Table 2.

Clinical trials on AD subjects using statins

Reference	Phase	Statins	Cohort size	follow-up	Results
Shepherd et al. 2002 PROSPER study [42, 43]	III	pravastatin 40 mg/day	5804 subjects	3.2 years	no evident benefit in cognition
MRC/BHF study 2002 [44]	III	simvastatin 40 mg/day	20536 subjects	5 years	no differences in cognition
Sparks et al. 2003 ADCLT study [36]	II	atorvastatin 80 mg/day	67 subjects	1 year	positive effect on the ADAS-cog performance was observed in mild-to-moderate AD subjects
Rieske et al. 2006 [39, 40]	II	simvastatin 40 mg/day , pravastatin 80 mg/day	23 subjects	14 weeks	protective effect on AD development
Carlsson et al. 2008 [41]	II	simvastatin 40 mg/day	57 subjects	4 months	improved cognitive function in middle-aged adults
Feldman et al. 2010 LEADe study [45, 46]	II	atorvastatin 80 mg/day	641	18 months	no benefits on AD treatment
Sano et al. 2011 CLASP-AD study [48]	II	simvastatin 20 mg/day for 6 weeks and then 40 mg/day	406	18 months	no benefits on AD treatment